These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 1884726)

  • 1. Improved bioavailability from a spironolactone beta-cyclodextrin complex.
    Yusuff NT; York P; Chrystyn H; Bramley PN; Swallow RD; Tuladhar BR; Losowsky MS
    Eur J Clin Pharmacol; 1991; 40(5):507-11. PubMed ID: 1884726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
    Abosehmah-Albidy AZ; York P; Wong V; Losowsky MS; Chrystyn H
    Br J Clin Pharmacol; 1997 Jul; 44(1):35-9. PubMed ID: 9241094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats.
    Kaukonen AM; Lennernäs H; Mannermaa JP
    J Pharm Pharmacol; 1998 Jun; 50(6):611-9. PubMed ID: 9680070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
    McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
    J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers.
    Xu FG; Zhang ZJ; Dong HJ; Tian Y; Liu Y; Chen Y
    Arzneimittelforschung; 2008; 58(3):117-21. PubMed ID: 18488807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bioavailability of spironolactone hydrochlorothiazide combination preparation.
    Rameis H; Hitzenberger G; Horwatitsch H
    Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):327-33. PubMed ID: 7107086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
    Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
    Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.
    Deroubaix X; Stockis A; Allemon AM; Lebacq E; Acerbi D; Ventura P
    Eur J Clin Pharmacol; 1995; 47(6):531-6. PubMed ID: 7768257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing comparative bioavailability of spironolactone tablets.
    Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
    J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
    Zuo Z; Tam YK; Diakur J; Wiebe LI
    J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
    Rameis H; Bacher S
    Wien Med Wochenschr; 1988 Apr; 138(6-7):156-60. PubMed ID: 3394332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo availability of spironolactone from oral dosage forms.
    Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
    J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of nasal powders of beta-cyclodextrin by insufflation.
    De Ascentiis A; Bettini R; Caponetti G; Catellani PL; Peracchia MT; Santi P; Colombo P
    Pharm Res; 1996 May; 13(5):734-8. PubMed ID: 8860429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of ursodeoxycholic acid bioavailability by 2-hydroxypropyl-beta-cyclodextrin complexation in healthy volunteers.
    Panini R; Vandelli MA; Forni F; Pradelli JM; Salvioli G
    Pharmacol Res; 1995; 31(3-4):205-9. PubMed ID: 7630860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of dipyridamole-beta-cyclodextrin complex in dogs.
    Stracciari GL; Malvisi J; Anfossi P; Fregnan GB
    Arch Int Pharmacodyn Ther; 1989; 300():7-13. PubMed ID: 2619427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.